Here is the text formatted with clean, professional paragraph breaks and standardized typography, ready to be added directly to your Drupal page. Per your instructions, no names have been bolded.
Differences among cells within a single glioblastoma tumor may influence the cancer’s response to chemotherapy. The findings, published by Brown faculty in Cell Reports, also identify a crucial factor that could help improve treatment for the aggressive brain cancer.
Glioblastoma is notoriously difficult to treat. One of the key reasons is that no two cells within the tumor behave exactly alike. Even inside one tumor, some cells may respond to treatment while others resist it, allowing the cancer to persist and grow. While scientists have known for decades that tumors are composed of diverse cells, the biological forces driving these differences, and their impact on treatment, have remained elusive.
“Traditionally, researchers have focused on the overall behavior of a tumor by studying the average response across all the individual cells, using differences between the cells to interpret the average,” says senior author Clark Chen, MD, PhD, a professor of neurosurgery at Brown and director of the Brain Tumor Program at Brown University Health.
“Our study fundamentally flipped that approach,” Chen says. “Rather than focusing on the average response, we focused on the differences between individual cells within the same tumor, and what we found could change how we treat glioblastoma.”
Chen’s team discovered that a small molecule called miR-181d acts like a master switch that helps control how much of a DNA-repair protein called MGMT each glioblastoma cell produces. MGMT is crucial because it allows cancer cells to fix the damage caused by chemotherapy, making them harder to kill.
The problem is that not all tumor cells make the same amount of MGMT: some produce a lot, while others make very little. This uneven production means that while some cells die during treatment, others survive to fuel tumor growth.
When glioblastoma tumors are treated with chemotherapy, levels of miR-181d fall. This change amplifies the differences among individual cells within the tumor, thereby allowing more cells to make more MGMT and survive treatment. The research team found that administering miR-181d into the tumor can reduce this effect, making the cancer cells behave more uniformly, and importantly, more likely to respond to chemotherapy.
The discovery has already led to the development of a new potential therapy aimed at improving patients’ responses to chemotherapy by stabilizing miR-181d levels within the tumor.
“This is an exciting step forward,” says Gatikrushna Singh, PhD, an assistant professor of neurosurgery at the University of Minnesota and the study’s lead author. “Scientifically, it helps explain why tumors maintain so much internal variability. Clinically, it opens the door to gene-therapy strategies that could be truly game-changing for many glioblastoma patients.”